{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:08:38Z","timestamp":1790366918429,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pituitary carcinomas (PCs), defined as distant metastases of pituitary neoplasms, are very rare malignancies. Because the clinical presentation of PCs is variable, early diagnosis and management remain challenging. PCs are always refractory to comprehensive treatments, and patients with PCs have extremely poor prognoses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We describe one case of a prolactin-secreting pituitary adenoma (PA) refractory to conventional therapy that evolved into a PC with intraspinal metastasis. A 34-year-old female was diagnosed with an invasive prolactin-secreting PA in 2009 and was unresponsive to medical treatment with bromocriptine. The tumor was gross totally removed via transsphenoidal surgery (TSS). However, the patient experienced multiple tumor recurrences or regrowth despite comprehensive treatments, including medical therapy, two gamma knife radiosurgeries (GKSs), and four frontal craniotomies. In 2016, she was found to have an intradural extramedullary mass at the level of the fourth lumbar vertebra. The intraspinal lesion was completely resected and was confirmed as a metastatic PC based on histomorphology and immunohistochemical staining. The literature on the diagnosis, molecular pathogenesis, treatment, and prognosis of patients with prolactin-secreting PCs was reviewed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PCs are very rare neoplasms with variable clinical features and poor prognosis. Most PCs usually arise from aggressive PAs refractory to conventional therapy. There is no reliable marker to identify aggressive PAs with a risk for progression to PCs; thus, it is difficult to diagnose these PCs early until the presence of metastatic lesions. It is still very challenging to manage patients with PCs due to a lack of standardized protocols for diagnosis and treatment. Establishing molecular biomarkers and the pathobiology of PCs could help in the early identification of aggressive PAs most likely to evolve into PCs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-021-00874-8","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T10:04:04Z","timestamp":1635501844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review"],"prefix":"10.1186","volume":"21","author":[{"given":"Congxin","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusen","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honggang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"issue":"3","key":"874_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","volume":"28","author":"O Mete","year":"2017","unstructured":"Mete O, Lopes MB. Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol. 2017;28(3):228\u201343. https:\/\/doi.org\/10.1007\/s12022-017-9498-z.","journal-title":"Endocr Pathol"},{"issue":"02","key":"874_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1055\/s-0039-1683435","volume":"81","author":"RM Carey","year":"2020","unstructured":"Carey RM, Kuan EC, Workman AD, Patel NN, Kohanski MA, Tong CCL, et al. A population-level analysis of pituitary carcinoma from the national Cancer database. J Neurol Surg B Skull Base. 2020;81(02):180\u20136. https:\/\/doi.org\/10.1055\/s-0039-1683435.","journal-title":"J Neurol Surg B Skull Base"},{"issue":"1","key":"874_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4103\/jnrp.jnrp_325_17","volume":"9","author":"LR Moscote-Salazar","year":"2018","unstructured":"Moscote-Salazar LR, Satyarthee GD, Calderon-Miranda WG, Matus JA, Pacheco-Hernandez A, Puac-Polanco PC, et al. Prolactin secreting pituitary carcinoma with extracranial spread presenting with pathological fracture of femur. J Neurosci Rural Pract. 2018;9(1):170\u20133. https:\/\/doi.org\/10.4103\/jnrp.jnrp_325_17.","journal-title":"J Neurosci Rural Pract"},{"issue":"4","key":"874_CR4","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.3171\/foc.2004.16.4.8","volume":"16","author":"BT Ragel","year":"2004","unstructured":"Ragel BT, Couldwell WT. Pituitary carcinoma: a review of the literature. Neurosurg Focus. 2004;16(4):E7. https:\/\/doi.org\/10.3171\/foc.2004.16.4.8.","journal-title":"Neurosurg Focus"},{"issue":"11","key":"874_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nrc926","volume":"2","author":"SL Asa","year":"2002","unstructured":"Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer. 2002;2(11):836\u201349. https:\/\/doi.org\/10.1038\/nrc926.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"874_CR6","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769\u201375. https:\/\/doi.org\/10.1210\/jc.2006-1668.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"874_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. 2010;72(3):377\u201382. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03667.x.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"874_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ecl.2014.10.008","volume":"44","author":"A Sav","year":"2015","unstructured":"Sav A, Rotondo F, Syro LV, Di Ieva A, Cusimano MD, Kovacs K. Invasive, atypical and aggressive pituitary adenomas and carcinomas. Endocrinol Metab Clin. 2015;44(1):99\u2013104. https:\/\/doi.org\/10.1016\/j.ecl.2014.10.008.","journal-title":"Endocrinol Metab Clin"},{"issue":"4","key":"874_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","volume":"134","author":"MBS Lopes","year":"2017","unstructured":"Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521\u201335. https:\/\/doi.org\/10.1007\/s00401-017-1769-8.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"874_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11060-014-1413-6","volume":"117","author":"A Heaney","year":"2014","unstructured":"Heaney A. Management of aggressive pituitary adenomas and pituitary carcinomas. J Neuro-Oncol. 2014;117(3):459\u201368. https:\/\/doi.org\/10.1007\/s11060-014-1413-6.","journal-title":"J Neuro-Oncol"},{"issue":"12","key":"874_CR11","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1210\/jc.2011-2031","volume":"96","author":"AP Heaney","year":"2011","unstructured":"Heaney AP. Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab. 2011;96(12):3649\u201360. https:\/\/doi.org\/10.1210\/jc.2011-2031.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"874_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1227\/01.NEU.0000349930.66434.82","volume":"65","author":"F Salehi","year":"2009","unstructured":"Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M. Ki-67 in pituitary neoplasms: a review--part I. Neurosurgery. 2009;65(3):429\u201337. https:\/\/doi.org\/10.1227\/01.NEU.0000349930.66434.82.","journal-title":"Neurosurgery"},{"issue":"4","key":"874_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.nec.2012.06.009","volume":"23","author":"MC Oh","year":"2012","unstructured":"Oh MC, Tihan T, Kunwar S, Blevins L, Aghi MK. Clinical Management of Pituitary Carcinomas. Neurosurg Clin N Am. 2012;23(4):595\u2013606. https:\/\/doi.org\/10.1016\/j.nec.2012.06.009.","journal-title":"Neurosurg Clin N Am"},{"issue":"4","key":"874_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.14310\/horm.2002.1380","volume":"11","author":"J Phillips","year":"2012","unstructured":"Phillips J, East HE, French SE, Melcescu E, Hamilton RD, Nicholas WC, et al. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? Hormones (Athens, Greece). 2012;11(4):477.","journal-title":"Hormones (Athens, Greece)"},{"key":"874_CR15","doi-asserted-by":"publisher","unstructured":"Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WJ, et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer Am Cancer Soc. 1997;79(4):804\u201312. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3.","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3"},{"issue":"4","key":"874_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1227\/00006123-199604000-00027","volume":"38","author":"K Thapar","year":"1996","unstructured":"Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws EJ. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery. 1996;38(4):765\u201370, 770-771. https:\/\/doi.org\/10.1227\/00006123-199604000-00027.","journal-title":"Neurosurgery"},{"issue":"2","key":"874_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3171\/jns.2002.96.2.0352","volume":"96","author":"TA Gaffey","year":"2002","unstructured":"Gaffey TA, Scheithauer BW, Lloyd RV, Burger PC, Robbins P, Fereidooni F, et al. Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg. 2002;96(2):352.","journal-title":"J Neurosurg"},{"issue":"10","key":"874_CR18","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1210\/jcem.84.10.6066","volume":"84","author":"K Lidhar","year":"1999","unstructured":"Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab. 1999;84(10):3823\u201330. https:\/\/doi.org\/10.1210\/jcem.84.10.6066.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"874_CR19","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1210\/jcem.74.4.1312542","volume":"74","author":"HJ Karga","year":"1992","unstructured":"Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL. Ras mutations in human pituitary tumors. J Clin Endocrinol Metab. 1992;74(4):914\u20139. https:\/\/doi.org\/10.1210\/jcem.74.4.1312542.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"874_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1210\/jcem.78.4.8157709","volume":"78","author":"L Pei","year":"1994","unstructured":"Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D. H-ras mutations in human pituitary carcinoma metastases. J Clin Endocrinol Metab. 1994;78(4):842\u20136. https:\/\/doi.org\/10.1210\/jcem.78.4.8157709.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"874_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1210\/jcem.78.1.8288721","volume":"78","author":"WY Cai","year":"1994","unstructured":"Cai WY, Alexander JM, Hedley-Whyte ET, Scheithauer BW, Jameson JL, Zervas NT, et al. Ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocrinol Metab. 1994;78(1):89\u201393. https:\/\/doi.org\/10.1210\/jcem.78.1.8288721.","journal-title":"J Clin Endocrinol Metab"},{"key":"874_CR22","doi-asserted-by":"publisher","unstructured":"Bajaj S, Kumar MS, Peters GJ, Mayur YC. Targeting telomerase for its advent in cancer therapeutics. Med Res Rev. 2020;40(5):1871\u2013919. https:\/\/doi.org\/10.1002\/med.21674.","DOI":"10.1002\/med.21674"},{"issue":"3","key":"874_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0090-3019(00)00181-6","volume":"53","author":"K Harada","year":"2000","unstructured":"Harada K, Arita K, Kurisu K, Tahara H. Telomerase activity and the expression of telomerase components in pituitary adenoma with malignant transformation. Surg Neurol. 2000;53(3):267\u201374. https:\/\/doi.org\/10.1016\/S0090-3019(00)00181-6.","journal-title":"Surg Neurol"},{"issue":"11","key":"874_CR24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s40618-015-0298-3","volume":"38","author":"CS Martins","year":"2015","unstructured":"Martins CS, Santana-Lemos BA, Saggioro FP, Neder L, Machado HR, Moreira AC, et al. Telomere length and telomerase expression in pituitary tumors. J Endocrinol Investig. 2015;38(11):1243\u20136. https:\/\/doi.org\/10.1007\/s40618-015-0298-3.","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"874_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter D. Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology. 2019;109(1):42\u201350. https:\/\/doi.org\/10.1159\/000495775.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"874_CR26","first-page":"231","volume":"32","author":"E Guastamacchia","year":"2007","unstructured":"Guastamacchia E, Triggiani V, Tafaro E, De Tommasi A, De Tommasi C, Luzzi S, et al. Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report. Minerva Endocrinol. 2007;32(3):231\u20136.","journal-title":"Minerva Endocrinol"},{"issue":"12","key":"874_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1136\/jnnp.55.12.1205","volume":"55","author":"T Petterson","year":"1992","unstructured":"Petterson T, MacFarlane IA, MacKenzie JM, Shaw MD. Prolactin secreting pituitary carcinoma. J Neurol Neurosurg Psychiatry. 1992;55(12):1205\u20136. https:\/\/doi.org\/10.1136\/jnnp.55.12.1205.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"874_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/nop\/npv059","volume":"3","author":"Y Ji","year":"2016","unstructured":"Ji Y, Vogel RI, Lou E. Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports. Neurooncol Pract. 2016;3(3):188\u201395. https:\/\/doi.org\/10.1093\/nop\/npv059.","journal-title":"Neurooncol Pract"},{"issue":"2","key":"874_CR29","first-page":"139","volume":"16","author":"MH Almalki","year":"2017","unstructured":"Almalki MH, Aljoaib NN, Alotaibi MJ, Aldabas BS, Wahedi TS, Ahmad MM, et al. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. Hormones (Athens, Greece). 2017;16(2):139.","journal-title":"Hormones (Athens, Greece)"},{"issue":"6","key":"874_CR30","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1530\/EJE-16-0979","volume":"176","author":"H Lasolle","year":"2017","unstructured":"Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, et al. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol. 2017;176(6):769\u201377. https:\/\/doi.org\/10.1530\/EJE-16-0979.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"874_CR31","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2017","unstructured":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2017;178(1):G1\u2013G24. https:\/\/doi.org\/10.1530\/EJE-17-0796.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"874_CR32","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s11102-012-0434-4","volume":"16","author":"R S\u00e1nchez-Ortiga","year":"2013","unstructured":"S\u00e1nchez-Ortiga R, S\u00e1nchez-Tejada L, Moreno-Perez O, Riesgo P, Niveiro M, Pic\u00f3 Alfonso AM. Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary. 2013;16(3):370\u20137. https:\/\/doi.org\/10.1007\/s11102-012-0434-4.","journal-title":"Pituitary"},{"issue":"3","key":"874_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11102-011-0346-8","volume":"15","author":"LD Ortiz","year":"2012","unstructured":"Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, et al. Anti-VEGF therapy in pituitary carcinoma. Pituitary. 2012;15(3):445\u20139. https:\/\/doi.org\/10.1007\/s11102-011-0346-8.","journal-title":"Pituitary"},{"key":"874_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jocn.2017.02.052","volume":"41","author":"W Touma","year":"2017","unstructured":"Touma W, Hoostal S, Peterson RA, Wiernik A, SantaCruz KS, Lou E. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. J Clin Neurosci. 2017;41:75\u20137. https:\/\/doi.org\/10.1016\/j.jocn.2017.02.052.","journal-title":"J Clin Neurosci"},{"issue":"8","key":"874_CR35","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3390\/jcm8081107","volume":"8","author":"MD Ilie","year":"2019","unstructured":"Ilie MD, Lasolle H, Raverot G. Emerging and novel treatments for pituitary tumors. J Clin Med. 2019;8(8):1107. https:\/\/doi.org\/10.3390\/jcm8081107.","journal-title":"J Clin Med"},{"issue":"7","key":"874_CR36","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/onc.2016.264","volume":"36","author":"R Chen","year":"2017","unstructured":"Chen R, Duan J, Li L, Ma Q, Sun Q, Ma J, et al. mTOR promotes pituitary tumor development through activation of PTTG1. Oncogene. 2017;36(7):979\u201388. https:\/\/doi.org\/10.1038\/onc.2016.264.","journal-title":"Oncogene"},{"issue":"4","key":"874_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2217\/cns-2016-0011","volume":"5","author":"LE Donovan","year":"2016","unstructured":"Donovan LE, Arnal AV, Wang S, Odia Y. Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. CNS Oncol. 2016;5(4):203\u20139. https:\/\/doi.org\/10.2217\/cns-2016-0011.","journal-title":"CNS Oncol"},{"issue":"10","key":"874_CR38","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1210\/jc.2018-01347","volume":"103","author":"AL Lin","year":"2018","unstructured":"Lin AL, Jonsson P, Tabar V, Yang TJ, Cuaron J, Beal K, et al. Marked response of a Hypermutated ACTH-secreting pituitary carcinoma to Ipilimumab and Nivolumab. J Clin Endocrinol Metab. 2018;103(10):3925\u201330. https:\/\/doi.org\/10.1210\/jc.2018-01347.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"874_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","volume":"31","author":"M Caccese","year":"2020","unstructured":"Caccese M, Barbot M, Ceccato F, Padovan M, Gardiman MP, Fassan M, et al. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. Anticancer Drug Des. 2020;31(2):199\u2013204. https:\/\/doi.org\/10.1097\/CAD.0000000000000856.","journal-title":"Anticancer Drug Des"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00874-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00874-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00874-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T21:03:07Z","timestamp":1635541387000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00874-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["874"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00874-8","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"assertion":[{"value":"5 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s spouse for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have potential financial conflicts of interest related to this article, and all the authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}